USA flag logo/image

An Official Website of the United States Government

PREVENTION OF BIOFILMS IN MEDICAL DEVICES

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
65961
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
AI052701
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ALTUS BIOLOGICS, INC.
ALTUS BIOLOGICS, INC. 625 PUTNAM AVE CAMBRIDGE, MA 02139 0480
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: PREVENTION OF BIOFILMS IN MEDICAL DEVICES
Agency: HHS
Contract: 1R43AI052701-01A1
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Design of new efficient drug delivery systems for proteins is one of the major themes of modern biotechnology and biopharmaceutical industry. We found that cross-linked enzyme crystals (CLECs) show remarkable stability at various pHs, on storage, against proteolysis and organic solvents. These properties make them ideal for treatment against biofilm formation on medical devices /implants such as urethral catheters, ureteric and prostatic stents, penile and testicular implants, artificial urinary sphincters, prostheses for hip and knee replacements, shunts for hydrocephalus, vascular grafts, heart valves, vascular access devices, voice prostheses, etc. In addition, the CLECS can be used for the prevention of blood clot formation, for example, in venous catheters. The CLEC agent will be used to coat the medical devices for the prevention of formation of bacterial biofilms on these devices as well as the prevention of blood clots. The biofilms form on the above medical devices by colonization of bacteria embedded in a matrix, which become resistant to commonly used antibiotics. In this Phase I study, we propose to develop two prototypes of CLECs of enzyme - Serratiopeptidase and Streptokinase for prevention of biofilms by Pseudomonas aeruginosa and Staphylococcus aureus microorganisms. The coating will prevent the adherence of these bacteria to medical devices. Currently, there are more than 850,000 case infections associated with aid devices annually in the United States. These may be associated with as many as 100,000 deaths per year. The CLECs of Serratiopeptidase and Streptokinase have enormous commercial potential over the currently available treatment for the prevention of contamination of medical devices by minimizing the need for replacement once they are implanted. The CLECs of Serratiopeptidase and Streptokinase will also be important in preventing biofilm-related infections which are resistant to commercially available antibiotics.

Principal Investigator:

Bhami C. Shenoy
6172992941
SHENOY@ALTUS.COM

Business Contact:

Jonathan Lieber
6172992971
JLIEBER@ALTUS.COM
Small Business Information at Submission:

ALTUS BIOLOGICS, INC.
ALTUS BIOLOGICS, INC. 625 PUTNAM AVE CAMBRIDGE, MA 02139

EIN/Tax ID: 043573277
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No